INVA250117C30000
- 0.00
- 0.000.00%
Innoviva Newsroom
Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 25% Since Then
Express News | Innoviva Inc: Innoviva Specialty Therapeutics Anticipates Commercializing Zevtera in Mid-Year 2025
Express News | Innoviva Inc: Under Terms of Agreement, Innoviva, Inc., Will Be Granted Exclusive Marketing Rights to Zevtera in U.S.
Express News | Basilea Pharmaceutica AG Allschwil - to Receive $4 Million Upfront Payment, up to $223 Million in Milestones
Press Release: Basilea Announces Agreement With Innoviva Specialty Therapeutics for the Commercialization of Antibiotic Zevtera(R) (Ceftobiprole) in the United States
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
Innoviva Reports Strong Q3 Growth Amidst Strategic Advances
Innoviva to Participate in the UBS Global Healthcare Conference
Innoviva, Inc.'s (NASDAQ:INVA) Business Is Yet to Catch Up With Its Share Price
Innoviva GAAP EPS of $0.02, Revenue of $89.51M Beats by $12.59M
Innoviva Reports Q3 EPS 2c, Two Estimates 26c
Innoviva | 10-Q: Q3 2024 Earnings Report
Innoviva | 8-K: Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $89.5M
Express News | Innoviva Q3 Net Income USD 1.213 Million
Press Release: Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
Innoviva 3Q EPS 2c >INVA
Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024
Innoviva, Inc.'s (NASDAQ:INVA) Stock Is Going Strong: Have Financials A Role To Play?
Innoviva to Participate in Upcoming Investor Conferences